Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands ...

The FDA cleared the Omnipod 5, the 1st device to enable automated insulin injection for those with type 2 diabetes.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management Syste ...

Insulet Corporation PODD recently announced the commercial introduction of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for people with type 1 diabetes (T1D) who are two years of ...

PITTSBURGH — Patients with Type 1 diabetes are getting help managing it with a new device. Families in Pittsburgh have been waiting a long time for the Omnipod 5 and it wasn’t very easy to get ...

The Food and Drug Administration on Monday approved Insulet's Omnipod 5 automated insulin delivery system for people with Type 2 diabetes.

Insulet delivered outstanding first-quarter performance, fueled by the rollout of the new Omnipod 5, which has been on fire since regulatory approval was received last fall.

The tubeless Omnipod 5 automated insulin delivery system, launched in the United Kingdom in 2023, was associated with improved time in range (TIR) at 1 year, with no increase in time below range ...

Insulet exited the fourth quarter of 2022 with better-than-expected earnings and revenues. The company’s performance benefited from record quarterly U.S. and Total Omnipod new customer starts ...